Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic and Extraglycemic Goals in Type 2 Diabetes: A ClinicalImpact Curriculum

Get patient-specific guidance on GLP-1 RA options using this Interactive Decision Support Tool. Then, review commentaries, perspectives, and slides from a panel of experts.
Zachary T. Bloomgarden, MD, MACE
Richard E. Pratley, MD
John J. Russell, MD
Neil Skolnik, MD
Robert S. Zimmerman, MD

NACE Emerging Challenges in Primary Care: Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic and Extraglycemic Goals in Type 2 Diabetes

A series of live, online Virtual Symposia offers the opportunity for physicians, nurse practitioners, physician assistants, and other healthcare providers to gather to learn about current issues in primary care and to interact with one another for engaging discussions and collaborative learning.

Live virtual symposia dates:

  • August 29, 2020, in Houston, Texas
  • October 17, 2020, in Nashville, Tennessee

Downloadable Slidesets

Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.

John J. Russell, MD Neil Skolnik, MD Released: December 23, 2019

Interactive Decision Support Tool

Access expert recommendations for GLP-1 receptor agonist therapy for patients with type 2 diabetes.

Martin J. Abrahamson, MD, FACP Zachary T. Bloomgarden, MD, MACE Anne Peters, MD Richard E. Pratley, MD Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: February 26, 2020 Expired: February 25, 2021

ClinicalThought

In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.

Zachary T. Bloomgarden, MD, MACE Physicians: maximum of 0.4 AMA PRA Category 1 Credits Registered Nurses: 0.4 Nursing contact hours Released: March 2, 2020 Expired: March 1, 2021

For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novo Nordisk

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?